Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

811
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
811
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

687
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
687
Skin Cancer01:30

Skin Cancer

6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of mobile nursing information systems on patient satisfaction with nursing care: a systematic review and meta-analysis.

BMC nursing·2026
Same author

A Multitask Prediction Framework for CircRNAs, Drugs, and Diseases Based on Multi-View Information Integration and Graph Contrastive Learning.

ACS synthetic biology·2026
Same author

Programmable optoelectronic memristors for energy-efficient adaptive binarized spiking neural networks.

Nanoscale·2026
Same author

Traumatic Brain Injury Enhances Susceptibility to Lung Bacterial Infection in Mice and Pigs by Modulating the Innate Immune Response.

Critical care medicine·2026
Same author

Nasal Aesthetic Restoration by Pre-expanded Paramedian Forehead Flap with Autologous Cartilage Framework and Laser Treatment.

Aesthetic plastic surgery·2026
Same author

Analysis of Molecular Epidemiological Characteristics of Porcine Reproductive and Respiratory Syndrome Virus Type 2 in Shandong Province from 2023 to 2025.

Veterinary sciences·2026

Related Experiment Video

Updated: Mar 13, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.

Yang Yang1,2, Jiaomiao Pei1, Guozhen Gao3

  • 1Department of Plastic and Reconstructive Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.

Oncotarget
|October 21, 2016
PubMed
Summary

This network meta-analysis found that immune checkpoint inhibitors and combination therapies significantly improve progression-free survival and overall survival in melanoma patients compared to chemotherapy. However, these advanced treatments may increase the risk of adverse events like pruritus and diarrhea.

Keywords:
chemotherapyipilimumabmelanomanivolumabtremelimumab

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Related Experiment Videos

Last Updated: Mar 13, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Melanoma remains a significant health concern, necessitating effective treatment strategies.
  • Chemotherapy has been a standard treatment, but newer immunotherapies offer potential advantages.

Purpose of the Study:

  • To compare the efficacy and tolerability of various melanoma management strategies.
  • To evaluate treatments including immune checkpoint inhibitors and combination therapies against chemotherapy.

Main Methods:

  • A network meta-analysis of randomized controlled trials was performed.
  • Data on progression-free survival (PFS), overall survival (OS), and objective response rates (ORR) were analyzed.
  • Adverse events, including pruritus and diarrhea, were assessed.

Main Results:

  • Ipilimumab, Tremelimumab, Nivolumab, Pembrolizumab (2 mg/kg), and Ipilimumab + Nivolumab significantly improved PFS over chemotherapy.
  • Ipilimumab, Nivolumab, and Ipilimumab + Chemotherapy improved OS compared to chemotherapy.
  • Nivolumab, Pembrolizumab (10 mg/kg and 2 mg/kg), and Ipilimumab + Nivolumab showed superior objective response rates.
  • Several interventions increased the risk of pruritus and diarrhea compared to chemotherapy.

Conclusions:

  • Immune checkpoint inhibitors and combination therapies demonstrate superior efficacy in improving survival and response rates for melanoma patients.
  • While effective, these advanced treatments are associated with a higher incidence of adverse events compared to traditional chemotherapy.